Roche reports HPV test data

Roche (SIX:ROG; OTCQX:RHHBY) reported data from the pivotal ATHENA trial of Cobas 4800 HPV test to determine risk for high-grade cervical disease. One in 10 women who tested positive for HPV genotypes 16 and/or 18 as determined by the test had cervical pre-cancer, even though their Pap test was normal. Specifically, the absolute risks of cervical intraepithelial neoplasia grade 2 (CIN2) or higher and CIN3 or higher in patients who tested positive for HPV 16 and/or 18 were 11.44% and 9.77%, respectively. The U.S. trial enrolled 46,867 women ages 30 and up undergoing routine cervical cancer screening. ...